Results 171 to 180 of about 27,568 (261)

Clinical Characteristics at the Diagnosis of New Primary Melanoma in Italy: A Multicenter Retrospective Study Before and After the COVID-19 Pandemic. [PDF]

open access: yesJ Clin Med
Pennacchioli E   +25 more
europepmc   +1 more source

Long-Term Survival with Daratumumab, Lenalidomide and Dexamethasone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients-A Survey from Two Italian Centers. [PDF]

open access: yesDiseases
Del Fabro V   +15 more
europepmc   +1 more source

Nanohybridization as a Route to a Water-Friendly Therapeutic Tool for Rescuing Misfolded Proteins. [PDF]

open access: yesACS Nanosci Au
Bortoluzzi M   +15 more
europepmc   +1 more source

Margin burden and postoperative management after transoral laser microsurgery for laryngeal glottic squamous cell carcinoma: a multicentre retrospective study on 1216 patients. [PDF]

open access: yesActa Otorhinolaryngol Ital
Chu F   +18 more
europepmc   +1 more source

An Integrated Approach in Assessing the Food-Related Properties of Microparticulated and Fermented Whey. [PDF]

open access: yesFoods
Khazzar S   +9 more
europepmc   +1 more source

Real-world safety and effectiveness of zanubrutinib vs ibrutinib in CLL: the CLL-ZANU2024 Italian cohort. [PDF]

open access: yesBlood Adv
Martino EA   +83 more
europepmc   +1 more source

An inverse probability of treatment weighted comparison between vedolizumab, ustekinumab, and tofacitinib in anti-TNF-experienced ulcerative colitis patients. [PDF]

open access: yesTher Adv Gastroenterol
Tursi A   +12 more
europepmc   +1 more source

Living with chronic rhinosinusitis with nasal polyposis (CRSwNP): an experience to amplify Italian patients' voices. [PDF]

open access: yesJ Patient Rep Outcomes
Bernardi L   +10 more
europepmc   +1 more source

Clinical activity and safety of nivolumab in combination with ipilimumab in metastatic melanoma: findings from REALIPINIVO, a real-world study. [PDF]

open access: yesFront Immunol
Caraglia F   +26 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy